Corcept Therapeutics Inc
CORT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001088856
In the last 90 days, Corcept Therapeutics Inc insiders filed 0 open-market purchases and 17 sales; 425 institutions reported holding it in 13F filings for Q2 2026, worth $7.15B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:10 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 26, 2025 | Jan 8, 2024 | Feb 28, 2023 | Feb 15, 2022 |
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M |
| Cost of revenue | $13.0M | $10.9M | $6.48M | $5.38M | $5.28M |
| Research and development | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M |
| Selling, general and administrative | $448.7M | $280.3M | $184.3M | $152.8M | $122.4M |
| Operating income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M |
| Income tax | -$33.2M | $20.3M | $18.4M | $14.8M | $12.5M |
| Net income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M |
| EPS, basic | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 |
| EPS, diluted | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| Weighted shares, basic | 103.9M | 103.2M | 103.6M | 106.8M | 115.7M |
| Weighted shares, diluted | 120.0M | 113.5M | 111.7M | 116.0M | 126.0M |
| Margins and growth | |||||
| Operating margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% |
| Net margin | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% |
| Revenue growth, year over year | +12.8% | +39.9% | +20.0% | +9.8% | +3.4% |
| Net income growth, year over year | −29.4% | +33.0% | +4.7% | −9.9% | +6.1% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 26, 2025 | Jan 8, 2024 | Feb 28, 2023 | Feb 15, 2022 |
| Cash and equivalents | $120.5M | $127.7M | $135.6M | $66.3M | $77.6M |
| Short-term investments | $251.7M | $255.7M | $232.7M | – | – |
| Accounts receivable | $59.8M | $54.0M | $41.1M | $31.1M | $27.6M |
| Inventory | $12.9M | $12.4M | $7.73M | $6.10M | $4.99M |
| Total current assets | $485.5M | $471.6M | $458.6M | $499.3M | $266.5M |
| Property, plant and equipment | $1.89M | $2.69M | $195.0K | $633.0K | $1.00M |
| Total assets | $836.7M | $840.6M | $621.5M | $583.4M | $423.8M |
| Accounts payable | $40.4M | $15.4M | $17.4M | $12.0M | $6.91M |
| Total current liabilities | $166.1M | $140.8M | $104.5M | $72.5M | $47.5M |
| Total liabilities | $188.8M | $161.0M | $114.8M | $81.6M | $48.0M |
| Shareholders' equity | $647.8M | $679.6M | $506.7M | $501.8M | $375.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 24, 2026 | Feb 26, 2025 | Jan 8, 2024 | Feb 28, 2023 | Feb 15, 2022 |
| Operating cash flow | $142.0M | $198.1M | $127.0M | $120.3M | $167.9M |
| Capital expenditures | $211.0K | $2.17M | $139.0K | $413.0K | $469.0K |
| Free cash flow | $141.8M | $195.9M | $126.9M | $119.9M | $167.4M |
| Depreciation and amortization | $1.15M | $795.0K | $577.0K | $782.0K | $1.07M |
| Stock-based compensation | $84.5M | $61.4M | $48.9M | $42.4M | $42.9M |
| Share buybacks | $172.9M | $15.7M | – | – | – |
| Investing cash flow | $69.8M | -$177.6M | $90.9M | -$114.3M | $136.1M |
| Financing cash flow | -$220.4M | -$28.3M | -$148.7M | -$17.3M | -$302.6M |
| Net change in cash | -$7.17M | -$7.89M | $69.2M | -$11.3M | $1.43M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 11.1% | 9.1% | 10.1% | 10.6% | 11.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 22, 2026 | 109.4M | +4.0% | SEC |
| Jul 22, 2026 | 108.1M | +2.6% | SEC |
| Apr 23, 2026 | 107.4M | +1.2% | SEC |
| Feb 17, 2026 | 106.4M | +0.8% | SEC |
| Oct 23, 2025 | 105.2M | +0.4% | SEC |
| Jul 24, 2025 | 105.4M | +0.8% | SEC |
| Apr 28, 2025 | 106.0M | +1.9% | SEC |
| Feb 18, 2025 | 105.5M | +1.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.